Results 181 to 190 of about 12,381 (205)
Some of the next articles are maybe not open access.
Radioimmunotherapy of lymphoma
1993The development of radiolabeled monoclonal antibodies (MoAb) was a significant advance in the use of these molecules for the treatment of human neoplasms. Unlabeled murine MoAbs had proven to have modest activity against human neoplasms due to (1) the relatively poor interactions between the antibody Fc receptors and human effector cells, and (2) the ...
T M, Kuzel, S T, Rosen
openaire +2 more sources
Radioimmunotherapy for lymphoma
Current Opinion in Oncology, 1999After more than a decade of unfulfilled promises, radioimmunotherapy for the treatment of non-Hodgkin's lymphoma has been demonstrated to be efficacious in the treatment of refractory disease. It is likely that in the near future, the Food and Drug Administration will approve one or more radioimmunoconjugates for clinical use.
openaire +2 more sources
Bifunctional Antibodies for Radioimmunotherapy
Hybridoma, 1995In two-step targeting technique using bifunctional antibodies, a nonradiolabeled immunoconjugate with slow uptake kinetics (several days) is initially injected, followed by a small radiolabeled hapten with fast kinetics (several hours) that binds to the bispecific immunoconjugate already taken up by the tumor target.
J F, Chatal +5 more
openaire +2 more sources
An overview of radioimmunotherapy
Cancer Immunology Immunotherapy, 1991In reviewing the current state of affairs in radioimmunotherapy the paper focuses on the main difficulties thus far encountered and the procedures designed to avoid or circumvent these problems. The long range beta-emitters 90Y and 188Re have replaced 131I as the isotopes currently receiving most attention for use in radioimmunotherapy, and a range of ...
A, Maraveyas, A A, Epenetos
openaire +2 more sources
Recent developments in radioimmunotherapy
Clinical Oncology, 1994With the advent of monoclonal antibody techniques, there has been renewed interest in RIT as a treatment modality in patients with a variety of tumour types. There has been a considerable research effort to increase understanding of the scientific basis of such therapy at all levels.
K J, Harrington, A A, Epenetos
openaire +2 more sources
Radioimmunotherapy of Ovarian Cancer
Hybridoma, 1995Despite the advances in the management of ovarian cancer, the disease remains the leading cause of death from gynecological malignancies. As it generally remains confined to the peritoneal cavity, ovarian cancer is an attractive target for radioimmunotherapy via the intraperitoneal route of administration.
K N, Syrigos, A A, Epenetos
openaire +2 more sources
Microdosimetric concepts in radioimmunotherapy
Medical Physics, 1993In microdosimetry particular emphasis is placed on the stochastic fluctuation of dose in small target volumes such as individual cell nuclei or chromatin fiber, and their relevance to radiobiologic toxicity. Thus microdosimetry is intimately associated with models of radiation action.
J L, Humm +3 more
openaire +2 more sources
Review of clinical radioimmunotherapy
Expert Review of Anticancer Therapy, 2006Radioimmunotherapy involves a form of biologically targeted radiopharmaceutical treatment in which a radioactive isotope (typically a short-range, high-energy beta-emitter) is chemically bound to a target-specific monoclonal antibody or fragment. Thus, these radioimmunoconjugates combine the exquisite targeting specificity of the humoral immune system ...
Brad, Pohlman +2 more
openaire +2 more sources
Radioimmunotherapy in Brain Tumors
2012Gliomas and meningiomas are the most frequent primary brain tumors. Surgery, external beam radiotherapy, and chemotherapy are, at present, the essential components in the therapeutic management of malignant brain masses. Nevertheless, these methods present limitations in terms of clinical response and rate of toxicity and morbidity. Because of the need
Grana, Chiara Maria, Paganelli, Giovanni
openaire +2 more sources